Meta-analysis of Second-trimester Markers for Trisomy 21
Overview
Affiliations
Objective: To summarize by meta-analysis the accumulated data on the screening performance of second-trimester sonographic markers for fetal trisomy 21.
Methods: We conducted a literature search to identify studies between 1995 and September 2012 that provided data on the incidence of sonographic markers in trisomy 21 and euploid fetuses at 14-24 weeks' gestation. Weighted independent estimates of detection rate, false-positive rate and positive and negative likelihood ratios (LR) of markers were calculated.
Results: A total of 48 studies was included in the analysis. The pooled estimates of positive and negative LR were, respectively: 5.83 (95% CI, 5.02-6.77) and 0.80 (95% CI, 0.75-0.86) for intracardiac echogenic focus; 27.52 (95% CI, 13.61-55.68) and 0.94 (95% CI, 0.91-0.98) for ventriculomegaly; 23.30 (95% CI, 14.35-37.83) and 0.80 (95% CI, 0.74-0.85) for increased nuchal fold; 11.44 (95% CI, 9.05-14.47) and 0.90 (95% CI, 0.86-0.94) for hyperechogenic bowel; 7.63 (95% CI, 6.11-9.51) and 0.92 (95% CI, 0.89-0.96) for mild hydronephrosis; 3.72 (95% CI, 2.79-4.97) and 0.80 (95% CI, 0.73-0.88) for short femur; 4.81 (95% CI, 3.49-6.62) and 0.74 (95% CI, 0.63-0.88) for short humerus; 21.48 (95% CI, 11.48-40.19) and 0.71 (95% CI, 0.57-0.88) for aberrant right subclavian artery (ARSA); and 23.27 (95% CI, 14.23-38.06) and 0.46 (95% CI, 0.36-0.58) for absent or hypoplastic nasal bone. The combined negative LR, obtained by multiplying the values of individual markers, was 0.13 (95% CI, 0.05-0.29) when short femur but not short humerus was included and 0.12 (95% CI, 0.06-0.29) when short humerus but not short femur was included.
Conclusion: The presence of sonographic markers increases, and absence of such markers decreases, the risk for trisomy 21. In the case of most isolated markers there is only a small effect on modifying the pre-test odds for trisomy 21, but with ventriculomegaly, nuchal fold thickness and ARSA there is a 3-4-fold increase in risk and with hypoplastic nasal bone a 6-7-fold increase.
Reproductive surgery remains an essential element of reproductive medicine.
Urman B, Ata B, Gomel V Facts Views Vis Obgyn. 2024; 16(2):145-162.
PMID: 38950529 PMC: 11366118. DOI: 10.52054/FVVO.16.2.022.
Liu Y, Liu S, Liu J, Bai T, Jing X, Deng C Orphanet J Rare Dis. 2024; 19(1):56.
PMID: 38336695 PMC: 10858470. DOI: 10.1186/s13023-024-03066-4.
Importance of a detailed anomaly scan after a cfDNA test indicating fetal trisomy 21, 18 or 13.
Spingler T, Sonek J, Hoopmann M, Prodan N, Jonaityte G, Elger T Arch Gynecol Obstet. 2023; 310(2):749-755.
PMID: 38091054 PMC: 11258052. DOI: 10.1007/s00404-023-07311-2.
Single nucleotide polymorphism array (SNP-array) analysis for fetuses with abnormal nasal bone.
Xie X, Su L, Li Y, Shen Q, Wang M, Wu X Arch Gynecol Obstet. 2023; 309(6):2475-2482.
PMID: 37430178 DOI: 10.1007/s00404-023-07122-5.
Measurement of the Fetal Ear Length Has No Clinical Value.
Witkowski S, Respondek-Liberska M, Zielinski R, Strzelecka I J Clin Med. 2023; 12(9).
PMID: 37176530 PMC: 10179669. DOI: 10.3390/jcm12093084.